Discounted Cash Flow (DCF) Analysis Levered

CRISPR Therapeutics AG (CRSP)

$71.47

-1.48 (-2.03%)
All numbers are in Millions, Currency in USD
Stock DCF: -961,044,561,146,797,056.00 | 71.47 | overvalue

Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue 289.590.54913.080.44370234,038.54148,039,618.7593,641,535,913.1059,232,368,486,369.5937,467,064,612,876,600
Revenue (%)
Operating Cash Flow 56.68-238.37538.97-495.74-260.38-73,765,769.51-46,660,076,629.20-29,514,539,948,040.45-18,669,237,842,600,004-11,809,109,755,299,053,568
Operating Cash Flow (%)
Capital Expenditure -6.68-18.36-81.71-37.19-11.97-5,581,726.33-3,530,686,116.13-2,233,313,443,664.24-1,412,668,465,449,417.50-893,574,611,721,737,088
Capital Expenditure (%)
Free Cash Flow 49.99-256.72457.27-532.93-272.35-79,347,495.84-50,190,762,745.33-31,747,853,391,704.69-20,081,906,308,049,420-12,702,684,367,020,789,760

Weighted Average Cost Of Capital

Share price $ 71.47
Beta 1.780
Diluted Shares Outstanding 79.22
Cost of Debt
Tax Rate -1.92
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.758
Total Debt 238.63
Total Equity 5,661.92
Total Capital 5,900.55
Debt Weighting 4.04
Equity Weighting 95.96
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue 289.590.54913.080.44370234,038.54148,039,618.7593,641,535,913.1059,232,368,486,369.5937,467,064,612,876,600
Operating Cash Flow 56.68-238.37538.97-495.74-260.38-73,765,769.51-46,660,076,629.20-29,514,539,948,040.45-18,669,237,842,600,004-11,809,109,755,299,053,568
Capital Expenditure -6.68-18.36-81.71-37.19-11.97-5,581,726.33-3,530,686,116.13-2,233,313,443,664.24-1,412,668,465,449,417.50-893,574,611,721,737,088
Free Cash Flow 49.99-256.72457.27-532.93-272.35-79,347,495.84-50,190,762,745.33-31,747,853,391,704.69-20,081,906,308,049,420-12,702,684,367,020,789,760
WACC
PV LFCF -70,568,744.08-39,699,233,516.13-22,333,246,288,652.82-12,563,816,618,449,410-7,067,915,070,735,883,264
SUM PV LFCF -7,080,501,260,370,423,808

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 12.44
Free cash flow (t + 1) -12,956,738,054,361,206,784
Terminal Value -124,106,686,344,456,011,776
Present Value of Terminal Value -69,054,342,645,120,704,512

Intrinsic Value

Enterprise Value -76,134,843,905,491,124,224
Net Debt -150.84
Equity Value -76,134,843,905,491,124,224
Shares Outstanding 79.22
Equity Value Per Share -961,044,561,146,797,056.00